TTNP

Titan Pharmaceuticals, Inc. (de)

Jul 16 • 04:00PM ET

4.72

Dollar change +0.13
Percentage change 2.76	%

Healthcare • Biotechnology • USA • NASD

Peers: BTAI AUPH AKBA CDTX CGEN AFMD EPIX PSTV ATAI MNOV

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.60	Insider Own	28.78%	Shs Outstand	0.91M	Perf Week	9.43%
Market Cap	4.31M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.65M	Perf Month	5.99%
Enterprise Value	2.36M	PEG	-	EPS next Q	-	Inst Own	1.61%	Short Float	1.74%	Perf Quarter	25.78%
Income	-4.21M	P/S	-	EPS this Y	-	Inst Trans	58.36%	Short Ratio	0.30	Perf Half Y	47.39%
Sales	0.00M	P/B	2.30	EPS next Y	-	ROA	-95.64%	Short Interest	0.01M	Perf YTD	44.68%
Book/sh	2.05	P/C	2.21	EPS next 5Y	-	ROE	-105.70%	52W High	14.80 -68.13%	Perf Year	6.59%
Cash/sh	2.13	P/FCF	-	EPS past 3/5Y	33.79% 79.02%	ROIC	-224.24%	52W Low	3.03 55.66%	Perf 3Y	-59.34%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.17% 5.48%	Perf 5Y	-97.71%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	27.21%	Oper. Margin	-	ATR (14)	0.28	Perf 10Y	-99.97%
Dividend Ex-Date	-	Quick Ratio	7.73	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	60.68	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	7.73	EPS Q/Q	50.43%	SMA20	7.10%	Beta	1.29	Target Price	27.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	4.41%	Rel Volume	0.06	Prev Close	4.59
Employees	-	LT Debt/Eq	0.00	Earnings	-	SMA200	17.29%	Avg Volume	37.50K	Price	4.72
IPO	Jan 18, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	2,388	Change	2.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-19	Initiated	Maxim Group	Buy	$4
Nov-10-17	Downgrade	ROTH Capital	Buy → Neutral

Jun-27-25 04:05PM	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock (GlobeNewswire)
Jun-04-25 08:50AM	Titan announces filing of registration statement for proposed combination (TipRanks)
Jun-03-25 08:45AM	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. (GlobeNewswire)
May-14-25 06:49PM	Titan Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
Apr-11-25 04:15PM	Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock (GlobeNewswire)
06:00PM	Loading…
Mar-20-25 06:00PM	Titan Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +14.80%
Jan-03-25 04:16PM	Titan Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
Nov-27-24 04:05PM	Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq (GlobeNewswire)
Aug-19-24 04:11PM	Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd. (GlobeNewswire) +99.20%
Aug-15-24 10:53PM	TTNP Stock Earnings: Titan Pharmaceuticals Reported Results for Q2 2024 (InvestorPlace) -8.73%
May-16-24 08:54AM	TTNP Stock Earnings: Titan Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
Jan-25-24 04:29PM	Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria (GlobeNewswire)
Dec-28-23 04:15PM	Titan Pharmaceuticals Announces Reverse Stock Split and Ratio (GlobeNewswire) +25.00%
Nov-14-23 07:23PM	Titan Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -6.12%
Oct-16-23 04:37PM	Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors (GlobeNewswire) +5.30%
07:30AM	Loading…
Sep-18-23 07:30AM	Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock (GlobeNewswire)
Aug-28-23 12:44PM	Unveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com) -11.36%
Aug-15-23 08:46AM	Titan Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
Jul-27-23 07:30AM	Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets (GlobeNewswire) +13.07%
Jan-27-23 07:00AM	Daily Vickers Top Buyers & Sellers for 01/27/2023 (Argus Research)
Dec-15-22 07:00AM	Titan Pharmaceuticals Provides Shareholder Update (GlobeNewswire) -7.66%
Dec-12-22 07:49AM	UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc. (GlobeNewswire) +6.12%
Nov-17-22 05:35AM	Titan Pharmaceuticals Third Quarter 2022 Earnings: US$0.18 loss per share (vs US$0.19 loss in 3Q 2021) (Simply Wall St.)
Aug-16-22 10:53AM	Titan Pharmaceuticals Announces Board Expansion and Management Changes (PR Newswire)
Jul-11-22 08:00AM	Activist Investing Nominates Slate of Highly Qualified Director Candidates for Election to the Board of Directors of Titan Pharmaceuticals at Upcoming Special Meeting of Stockholders (GlobeNewswire) -7.19%
Jul-09-22 09:07AM	Here's Why We're Watching Titan Pharmaceuticals' (NASDAQ:TTNP) Cash Burn Situation (Simply Wall St.)
Jul-05-22 08:00AM	Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant (PR Newswire) +13.70%
Jun-10-22 08:00AM	Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc. (GlobeNewswire) -11.30%
Apr-25-22 01:29PM	Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc. (GlobeNewswire)
Feb-02-22 12:27PM	Titan Pharmaceuticals Raises $5.5M Via Equity (Benzinga)
08:45AM	Loading…
08:45AM	Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market (PR Newswire)
Dec-21-21 08:00AM	Titan Pharmaceuticals to Explore Strategic Alternatives (PR Newswire) +22.43%
Nov-08-21 04:15PM	Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021 (PR Newswire)
Nov-05-21 04:30PM	Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021 (PR Newswire)
Oct-25-21 07:15AM	Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries (PR Newswire) +10.29%
Oct-12-21 08:00AM	Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement (PR Newswire) +10.49%
Aug-20-21 02:52PM	Here's Why Titan Pharmaceuticals (NASDAQ:TTNP) Must Use Its Cash Wisely (Simply Wall St.)
Aug-04-21 09:34AM	10 Pharma Companies Making Treatment for Opioid Overdose (Insider Monkey)
Jun-23-21 08:00AM	Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus (PR Newswire) +8.16%
Mar-31-21 04:30PM	Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K (PR Newswire)
Feb-01-21 07:30AM	Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program (PR Newswire) +9.81%
Jan-15-21 09:15AM	Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering (PR Newswire) -9.43%
Dec-16-20 08:00AM	Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (PR Newswire) -6.05%
Dec-01-20 04:56AM	TTNP: Coverage Discontinued (Zacks Small Cap Research) -26.27%
Nov-30-20 12:50PM	Titan Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
Nov-16-20 08:45AM	Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results (PR Newswire)
Nov-02-20 08:00AM	Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09 (PR Newswire) -22.31%
Oct-30-20 08:14AM	7 Penny Stocks to Watch in November (InvestorPlace)
Oct-28-20 03:00PM	Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering (PR Newswire) +29.88%
08:00AM	Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09 (PR Newswire)
Oct-26-20 06:30AM	Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon (PR Newswire) +9.11%
Oct-15-20 08:00AM	Titan Pharmaceuticals Provides a Strategic & Corporate Update (PR Newswire) -7.20%
Sep-24-20 09:00AM	Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering (PR Newswire) -12.66%
Sep-18-20 04:45PM	Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation (PR Newswire)
Sep-16-20 01:05PM	Here's What We Think About Titan Pharmaceuticals' (NASDAQ:TTNP) CEO Pay (Simply Wall St.)
Sep-15-20 08:30AM	Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare (PR Newswire) +16.47%
Sep-14-20 08:30AM	Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation (PR Newswire) -8.43%
Aug-26-20 05:45AM	TTNP: Indegene to Advance Probuphine Commercialization (Zacks Small Cap Research)
Aug-14-20 08:45AM	Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results (PR Newswire) -5.76%
Aug-10-20 04:30PM	Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020 (PR Newswire)
Jul-08-20 08:00AM	Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation (PR Newswire)
Jun-24-20 08:00AM	Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership (PR Newswire) +24.03%
Jun-16-20 08:00AM	Titan Pharmaceuticals Launches Virtual REMS Training For Probuphine Health Care Providers (PR Newswire)
Jun-01-20 05:20AM	TTNP: First Quarter 2020 Financial and Operational Results (Zacks Small Cap Research)
May-15-20 08:45AM	Titan Pharmaceuticals Reports First Quarter 2020 Financial Results (PR Newswire) -19.14%
May-11-20 04:03PM	Titan Pharmaceuticals To Report First Quarter 2020 Financial Results On May 15, 2020 (PR Newswire) +7.81%
Apr-09-20 06:15AM	TTNP: Full Year 2019 Financial and Operational Results (Zacks Small Cap Research)
Apr-02-20 09:47PM	Edited Transcript of TTNP earnings conference call or presentation 30-Mar-20 8:30pm GMT (Thomson Reuters StreetEvents)
Mar-31-20 12:43PM	Penny Stocks to Buy Using Technical Analysis for April 2020 (Investopedia) -14.65%
Mar-30-20 04:03PM	Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results (PR Newswire) +9.20%
02:30PM	Titan Pharmaceuticals, Inc. to Host Earnings Call (ACCESSWIRE)
Mar-26-20 08:00AM	Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2019 Financial Results On March 30, 2020 (PR Newswire)
Mar-05-20 09:00AM	Titan Pharmaceuticals Receives $5.9 Million From Exercise Of Warrants (PR Newswire) +12.57%
Feb-18-20 08:55AM	Did Changing Sentiment Drive Titan Pharmaceuticals's (NASDAQ:TTNP) Share Price Down A Disastrous 99%? (Simply Wall St.)
Jan-13-20 08:00AM	Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule (PR Newswire)
Jan-07-20 09:15AM	Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering (PR Newswire) -19.83%
Dec-30-19 08:00AM	Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors (PR Newswire) +22.72%
Dec-17-19 10:30AM	Should You Worry About Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) CEO Pay? (Simply Wall St.)
Dec-04-19 01:22PM	Edited Transcript of TTNP earnings conference call or presentation 14-Nov-19 9:30pm GMT (Thomson Reuters StreetEvents)
Dec-03-19 09:00AM	Titan Pharmaceuticals To Present At The First Annual BioTuesdays Pre-JPM Virtual Conference (PR Newswire) +20.43%
Nov-25-19 05:15AM	TTNP: Waiting for Revenue Turn (Zacks Small Cap Research)
Nov-14-19 04:03PM	Titan Pharmaceuticals Reports Third Quarter 2019 Financial Results (PR Newswire) +12.04% -11.98%
Nov-07-19 04:30PM	Titan Pharmaceuticals To Release Third Quarter 2019 Financial Results On November 14 - Conference Call To Follow (PR Newswire)
Oct-22-19 08:00AM	Titan Pharmaceuticals To Present Two Posters On Probuphine® At The 10th American Conference On Pharmacometrics (PR Newswire)
Oct-18-19 10:23AM	These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year (American City Business Journals) +5.11%
Oct-16-19 09:20AM	Titan Pharmaceuticals Announces Pricing Of $9.0 Million Underwritten Public Offering (PR Newswire) -51.02%
Oct-01-19 08:00AM	Titan Pharmaceuticals and Crossroads of Southern Nevada Announce Probuphine® Availability at Crossroads Rehabilitation Facilities (PR Newswire)
Sep-18-19 08:00AM	Titan Receives Approval For Second Year Of NIDA Grant Funding For Development Of A Nalmefene Implant (PR Newswire) +20.91%
Aug-30-19 08:01PM	Edited Transcript of TTNP earnings conference call or presentation 14-Aug-19 8:30pm GMT (Thomson Reuters StreetEvents) +16.93%
Aug-23-19 11:30AM	TTNP: Long on Opportunity, Short on Capital (Zacks Small Cap Research) -6.17%
Aug-17-19 09:59AM	Some Titan Pharmaceuticals (NASDAQ:TTNP) Shareholders Have Copped A 99% Share Price Wipe Out (Simply Wall St.)
Aug-16-19 07:33AM	The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission (Benzinga) +7.51%
Aug-14-19 04:03PM	Titan Pharmaceuticals Reports Second Quarter 2019 Financial Results (PR Newswire) -37.43%
07:32AM	Q2 Earnings Preview For Titan Pharmaceuticals (Benzinga)
Aug-09-19 05:00PM	Titan Pharmaceuticals To Release Second Quarter 2019 Financial Results On August 14 - Conference Call To Follow (PR Newswire)
Aug-07-19 09:15AM	Titan Pharmaceuticals Announces Pricing Of $2.1 Million Registered Direct Offering (PR Newswire) -27.38%
Jul-09-19 09:00AM	Titan Pharmaceuticals Expands Patient Access To Probuphine® Via Specialty Product Distribution Agreement With CVS Caremark (PR Newswire)
Jul-03-19 10:54AM	What Does Titan Pharmaceuticals, Inc.'s (NASDAQ:TTNP) Balance Sheet Tell Us About It? (Simply Wall St.)
Jun-26-19 09:10AM	Titan Pharmaceuticals And Molteni Receive European Regulatory Approval For Probuphine (PR Newswire) -5.56%
Jun-04-19 07:00AM	Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine® (PR Newswire) +11.61%

Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TTNP

Titan Pharmaceuticals, Inc. (de)

Upgrade your FINVIZ experience